LEADER 02314nam 2200361 450 001 9910688305203321 005 20230625114828.0 035 $a(CKB)5400000000045615 035 $a(NjHacI)995400000000045615 035 $a(EXLCZ)995400000000045615 100 $a20230625d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCurrent aspects of radiopharmaceutical chemistry /$fedited by Peter Breast 210 1$aBasel, Switzerland :$cMDPI - Multidisciplinary Digital Publishing Institute,$d[2018] 210 4$dİ2018 215 $a1 online resource (216 pages) $cillustrations 311 $a3-03897-163-4 320 $aIncludes bibliographical references. 330 $aPositron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging techniques which are widely used in nuclear medicine for the diagnosis and treatment follow-up of many major diseases. They use biomolecules as probes, which are labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. These probes are called radiopharmaceuticals. Their design and development require a rather interdisciplinary process involving many different disciplines of natural and health sciences. In addition to their diagnostic and therapeutic purposes in the field of nuclear medicine, radiopharmaceuticals provide powerful tools for in vivo pharmacology during the process of pre-clinical drug development to identify new drug targets, investigate the pathophysiology of diseases, discover potential drug candidates, and evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo. Furthermore, they allow molecular imaging studies in various small-animal models of disease, including genetically engineered animals. The current collection of articles provides unique examples covering all major aspects in the field. 606 $aRadioisotopes in pharmacology 615 0$aRadioisotopes in pharmacology. 676 $a615.10724 702 $abreast$b Peter 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910688305203321 996 $aCurrent Aspects of Radiopharmaceutical Chemistry$92948905 997 $aUNINA